Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Avalo Therapeutics, Inc. Common Stock

AVTX

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Last trade $6.97
Day change -$0.40 (-5.43%)
Day range $6.92 – $7.74
Volume 720,905
Market cap $426M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$426.16M
Price / earnings
—
Price / book
0.98×
Price / sales
7,222.99×
EV / sales
6,121.49×
EV / EBITDA
-3.78×

Profitability

Earnings per share
-$1.53
Return on assets
-18.41%
Return on equity
-20.31%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
16.63×
Quick ratio
16.63×
Cash ratio
2.7×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$63.47M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AVTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$59K$0$0$0$192K
Cost of revenue$0$0$0$0$0$0$0$87K
Gross profit$0$0$0$59K$0$0$0$105K
Selling, general and administrative$8.35M$8.1M$6.85M$6.53M$5.58M$5.24M$5.55M$5.23M
Research and development$15.05M$23.42M$14.05M$13.27M$13.62M$14.07M$9.12M$8.18M
Total operating expenses$23.4M$31.52M$20.9M$19.8M$19.2M$19.32M$14.67M$13.42M
Operating income-$23.4M-$31.52M-$20.9M-$19.74M-$19.2M-$19.32M-$14.67M-$13.31M
Interest expense$4.25M$2.76M$803K$0$1.11M$1.1M$1.15M$0
Income before taxes-$18.94M-$36.34M-$19.62M-$13.59M-$30.61M-$20.75M-$13.14M-$35.23M
Income taxes$7K$18K$12K$130K$11K$16K$8K$114K
Net income-$18.95M-$36.36M-$19.63M-$13.72M-$30.63M-$20.77M-$13.15M-$35.34M
Net income attributable to common shareholders-$18.95M-$36.36M-$19.63M-$13.72M-$30.63M-$20.77M-$13.15M-$35.16M
EBITDA-$23.38M-$31.5M-$20.88M-$19.73M-$19.14M-$19.18M-$14.53M-$13.24M
Basic earnings per share-$0.34-$0.83-$0.98-$0.75-$2.19-$1.92-$1.25-$3.43
Diluted earnings per share-$0.34-$0.83-$0.98-$0.75-$2.19-$1.92-$1.25-$3.29

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

Avalo Therapeutics, a clinical-stage biotech company focused on IL-1β pathway therapeutics, announced its inclusion in the Russell 2000 and Russell 3000 indexes effective June 26, 2026. The company's lead asset abdakibart, an anti-IL-1β monoclonal antibody, recently reported positive Phase 2 data in hidradenitis suppurativa, with plans to advance next-generation candidate AVTX-010.

GlobeNewswire Inc.

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

Avalo Therapeutics priced an underwritten public offering of 19.73 million shares at $17.75 per share and 1.4 million pre-funded warrants, expected to raise approximately $375 million in gross proceeds. The company plans to use the funds to advance clinical development of its lead asset abdakibart, including Phase 3 topline data release, following positive Phase 2 results in hidradenitis suppurativa. The offering is expected to close on May 7, 2026.

GlobeNewswire Inc.

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics, a clinical-stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, announced that management will participate in two investor conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25. The company's lead asset, AVTX-009, is currently in Phase 2 clinical trials for hidradenitis suppurativa.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 29, 20231-for-240reverse split
Jul 8, 20221-for-12reverse split
Sep 10, 20071-for-51reverse split